BiofarmLTS:0HTH 69 Interest Coverage is 4,879.57 as of Mar. 2026, which is 144% above its 10-year median of 2,003.62. GuruFocus rates LTS:0HTH with a GF Score™ of 69/100 and a GF Value™ of lei0.15. The stock has 6 warning signs investors should review. Among 685 Drug Manufacturers companies, Biofarm ranks better than 95.04% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Biofarm's
Operating Income
for the
three
months ended in Mar. 2026 was lei34.2 Mil. Biofarm's Interest Expense for the
three
months ended in Mar. 2026 was lei-0.0 Mil.
Biofarm's interest coverage for the quarter that ended in Mar. 2026 was 4,879.57.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Biofarm SA has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Biofarm's Interest Coverage or its related term are showing as below:
LTS:0HTH'
s Interest Coverage Range Over the Past 10 Years
Min: 764.88 Med: 2003.62 Max: 35885
Current: 2616.88
LTS:0HTH's Interest Coverage is ranked better than 95.04% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs LTS:0HTH: 2616.88
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Biofarm Interest Coverage Related Terms
Biofarm Interest Coverage Historical Data
* Premium members only.
The historical data trend for Biofarm's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LTS:0HTH vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofarm Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofarm's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Biofarm's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofarm (LTS:0HTH) has a Interest Coverage of 4,879.57 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biofarm and its competitors. This is 144% above median its historical median of 2,003.62. Over the past decade, Biofarm's Interest Coverage has ranged from 764.88 to 35,885.00. According to the industry distribution chart, Biofarm ranks #34 out of 685 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is Biofarm's Interest Coverage too high?
Biofarm's current Interest Coverage of 4,879.57 is 144% above median its 10-year median of 2,003.62. Over the past 10 years, this metric has ranged from a low of 764.88 to a high of 35,885.00. The Drug Manufacturers industry median Interest Coverage is 12.75. Biofarm's value of 4,879.57 is 38171.1% above this industry median. Based on the distribution chart, Biofarm ranks #34 out of 685 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofarm has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #34 out of 685 companies for Interest Coverage. This places Biofarm in the top 5% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Biofarm's value of 4,879.57 is 38171.1% above this benchmark. Historically, Biofarm's own Interest Coverage has ranged from 764.88 to 35,885.00 over the past decade. While the company's 10-year median is 2,003.62 vs. the industry median of 12.75, Biofarm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofarm's current Interest Coverage of 4,879.57 is 38171.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biofarm and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current Interest Coverage is 4,879.57, which is 144% above median its own 10-year median of 2,003.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Biofarm (LTS:0HTH) has a current Interest Coverage of 4,879.57. The stock's GF Value™ is lei0.15, compared to a current price of lei0.24 — trading 58% above its estimated fair value. The current Interest Coverage is 4,879.57, which is 144% above median its 10-year median of 2,003.62 and 38171.1% above the Drug Manufacturers industry median of 12.75. Biofarm's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Biofarm (LTS:0HTH), the current Interest Coverage is 4,879.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofarm (LTS:0HTH) Overvalued in 2026?
Based on GuruFocus' analysis, Biofarm stock appears to be overvalued.
The current stock price of lei0.24 is trading 58% above its estimated GF Value™ of lei0.15.
Key valuation signals for LTS:0HTH:
Interest Coverage: 4,879.57 (144% above median its 10-year median of 2,003.62)
GF Value™: lei0.15 vs. price of lei0.24 (58% above fair value)
Industry Position: 38171.1% above the Drug Manufacturers median (#34 of 685)
No single metric tells the full story. See the LTS:0HTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score
Get the complete analysis for LTS:0HTH
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTH has been successfully added to your 
